Aortic coarctation is a congenital heart disease characterised by the narrowing of the aorta, commonly resulting in increased morbidity and decreased life expectancy. Despite a relatively low number of affected patients (3 to 4 cases per 10 000 live births) the follow-up after intervention procedures is expensive, due to required ongoing monitoring of disease progression and relapse, and possible late complications. The potential loss of a large number of life years through early death in young patients and high costs of follow-up have put this disease in the focus of the FP7-funded CARDIOPROOF project, in which LSE Health is leading on evidence synthesis and economic modelling
